| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0006-2952(99)00167-7 |
| P698 | PubMed publication ID | 10449188 |
| P2093 | author name string | A. Pfeifer | |
| A. Boobis | |||
| J. Castell | |||
| K. Macé | |||
| M. J. Gómez-Lechón | |||
| R. Bort | |||
| P2860 | cites work | Diclofenac hepatitis | Q28324978 |
| Reversible hepatitis associated with diclofenac | Q28327886 | ||
| Diclofenac associated hepatitis | Q28333205 | ||
| Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. | Q34037250 | ||
| Simian virus 40 large tumor antigen-immortalized normal human liver epithelial cells express hepatocyte characteristics and metabolize chemical carcinogens | Q36338389 | ||
| Diclofenac-associated hepatotoxicity | Q37982787 | ||
| Pharmacokinetics and Metabolism of the Anti-Inflammatory Agent Voltaren | Q39615797 | ||
| Biotransformation of diclofenac sodium (Voltaren) in animals and in man. I. Isolation and identification of principal metabolites | Q39710218 | ||
| Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions | Q40841749 | ||
| Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis | Q40891684 | ||
| Aflatoxin B1-induced DNA adduct formation and p53 mutations in CYP450-expressing human liver cell lines | Q41102048 | ||
| Evaluation of triacetyloleandomycin, alpha-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. | Q41462331 | ||
| Culture of human hepatocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo | Q42479399 | ||
| Monooxygenase activity of human liver in microsomal fractions of needle biopsy specimens | Q43244964 | ||
| Immunochemical and catalytical studies on hepatic coumarin 7-hydroxylase in man, rat, and mouse | Q46192761 | ||
| High Expression of Human CYP2C in Immortalized Human Liver Epithelial Cells | Q47792300 | ||
| Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. | Q50998258 | ||
| Immunochemical detection of protein adducts in cultured human hepatocytes exposed to diclofenac | Q58681591 | ||
| Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 | Q67260608 | ||
| A new metabolite of diclofenac sodium in human plasma | Q68104380 | ||
| Diclofenac hepatitis | Q68625592 | ||
| Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver | Q70522450 | ||
| Interaction of sulfaphenazole derivatives with human liver cytochromes P450 2C: molecular origin of the specific inhibitory effects of sulfaphenazole on CYP 2C9 and consequences for the substrate binding site topology of CYP 2C9 | Q71916300 | ||
| Oxidation of diclofenac to reactive intermediates by neutrophils, myeloperoxidase, and hypochlorous acid | Q73257223 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Diclofenac | Q244408 |
| 5-hydroxydiclofenac | Q27126805 | ||
| 4',5-dihydroxydiclofenac | Q27225704 | ||
| P304 | page(s) | 787–796 | |
| P577 | publication date | 1999-09-01 | |
| P1433 | published in | Biochemical Pharmacology | Q864229 |
| P1476 | title | Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways | |
| P478 | volume | 58 |
| Q64099866 | A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate |
| Q36491320 | A human liver microphysiology platform for investigating physiology, drug safety, and disease models |
| Q44437706 | Analysis of diclofenac and its metabolites by high-performance liquid chromatography: relevance of CYP2C9 genotypes in diclofenac urinary metabolic ratios. |
| Q52887959 | Analysis of drug metabolism activities in a miniaturized liver cell bioreactor for use in pharmacological studies. |
| Q38912436 | CYP267A1 and CYP267B1 from Sorangium cellulosum So ce56 are Highly Versatile Drug Metabolizers |
| Q44432237 | CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers |
| Q38269162 | Comparative metabolism as a key driver of wildlife species sensitivity to human and veterinary pharmaceuticals |
| Q50062827 | Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: A multi-center study |
| Q37399435 | Cranberry juice suppressed the diclofenac metabolism by human liver microsomes, but not in healthy human subjects |
| Q58048739 | Cytochromes P450 as useful biocatalysts: addressing the limitations |
| Q28475945 | Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites |
| Q44643367 | Diclofenac induces apoptosis in hepatocytes |
| Q34575738 | Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety |
| Q28484663 | Diclofenac prolongs repolarization in ventricular muscle with impaired repolarization reserve |
| Q45120625 | Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity |
| Q57302790 | Drug metabolism and drug toxicity |
| Q34057571 | Drug-induced liver disease |
| Q33949227 | Drug-induced liver injury in older adults. |
| Q37598897 | Drug-induced liver injury: insights from genetic studies. |
| Q47305319 | Effect of body weight on fixed dose of diclofenac for the prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis |
| Q34409954 | Effect of itraconazole on the pharmacokinetics of diclofenac in beagle dogs |
| Q46885397 | Effect of voriconazole on the pharmacokinetics of diclofenac |
| Q58873968 | Electroanalysis of Cytochrome P450 3A4 Catalytic Properties with Nanostructured Electrodes: The Influence of Vitamin B Group on Diclofenac Metabolism |
| Q60182678 | Farmacogenómica clínica de CYP2C8 y CYP2C9: conceptos generales y aplicación al uso de AINE |
| Q38571414 | Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions |
| Q55287499 | Hepatocyte-based flow analytical bioreactor for online xenobiotics metabolism bioprediction. |
| Q46726532 | Identification of cytochrome P450 forms involved in the 4-hydroxylation of valsartan, a potent and specific angiotensin II receptor antagonist, in human liver microsomes |
| Q43932208 | In vitro metabolism of a novel antithrombotic compound, S002-333, and its enantiomers: quantitative cytochrome P450 phenotyping, metabolic profiling and enzyme kinetic studies |
| Q33792887 | Integrated Assessment of Diclofenac Biotransformation, Pharmacokinetics, and Omics-Based Toxicity in a Three-Dimensional Human Liver-Immunocompetent Coculture System |
| Q47744170 | Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain |
| Q48698056 | Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives |
| Q86527261 | Long-term culture and cryopreservation does not affect the stability and functionality of human embryonic stem cell-derived hepatocyte-like cells |
| Q43335420 | Occurrence of pharmaceuticals in municipal wastewater, in the recipient water, and sedimented particles of northern Lake Päijänne. |
| Q38130410 | PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. |
| Q37205954 | Pharmacogenetics of analgesics: toward the individualization of prescription |
| Q42284291 | Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans |
| Q50061402 | Potential of the strain Raoultella sp. KDF8 for removal of analgesics |
| Q90112951 | Preclinical Evaluation of Safety of Fucoidan Extracts From Undaria pinnatifida and Fucus vesiculosus for Use in Cancer Treatment |
| Q33998916 | Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children |
| Q51945395 | Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations. |
| Q37377886 | R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9. |
| Q44507637 | RP-HPLC study of the degradation of diclofenac and piroxicam in the presence of hydroxyl radicals |
| Q37121662 | Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. |
| Q46544571 | Relationship between CYP2C8 genotypes and diclofenac 5-hydroxylation in healthy Spanish volunteers |
| Q35049310 | Strategies and molecular probes to investigate the role of cytochrome P450 in drug metabolism: focus on in vitro studies. |
| Q34657381 | Sucralose, a synthetic organochlorine sweetener: overview of biological issues |
| Q32103802 | Summary of information on human CYP enzymes: human P450 metabolism data |
| Q28540307 | The curious case of benzbromarone: insight into super-inhibition of cytochrome P450 |
| Q53404414 | The hepatic reductase null mouse as a model for exploring hepatic conjugation of xenobiotics: application to the metabolism of diclofenac. |
| Q34367117 | The inhibitory activity of the extracts of popular medicinal herbs on CYP1A2, 2C9, 2C19 and 3A4 and the implications for herb-drug interaction. |
| Q46856531 | The potential of Hypoxis hemerocallidea for herb-drug interaction |
| Q34051372 | Transformation and removal pathways of four common PPCP/EDCs in soil |
| Q77129799 | Uncertainty factors for chemical risk assessment: interspecies differences in glucuronidation |
| Q38743580 | Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing |
Search more.